Skip to main content
Clinical Trials/IRCT20170315033086N8
IRCT20170315033086N8
Completed
Phase 2

Efficacy of inflawell capsules containing Boswellic acids on behavioral and cognitive symptoms and DTI changes in patients with frontotemporal dementia

Tehran University of Medical Sciences0 sites20 target enrollmentTBD

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Not specified
Sponsor
Tehran University of Medical Sciences
Enrollment
20
Status
Completed
Last Updated
5 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
5 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Behavioral variant of Frontotemporal dementia based on guideline: Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134
  • Language variant of Frontotemporal dementia based on guideline: Gorno\-Tempini ML, Hillis AE, Weintraub S, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011;76:1006\-1014

Exclusion Criteria

  • Other specific diseases of the central nervous system such as Parkinson's, multifactorial dementia, anterior brain dementia, Huntington's disease, hydrocephalus, brain tumors confirmed by MRI, severe paralysis of the nerve of the supernuclear body, epilepsy, clots between layers of brain tissue, multiple sclerosis and other dementias
  • Taking NSAIDs and systemic corticosteroids for previous two months continuously
  • Severe cardiovascular disease, kidney and liver disorders
  • Psychiatric disorders include bipolar disorder and schizophrenia under medication
  • Drugs or alcohol abuse
  • Brain\-related surgical interventions
  • head trauma and progressive degenerative motor disorder
  • Metabolic and systemic diseases

Outcomes

Primary Outcomes

Not specified

Similar Trials